Tryptophan
Tryptophan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against probable G-protein coupled receptor 139 and angiotensin-converting enzyme. In addition, it is known to target proton-coupled amino acid transporter 1, extracellular calcium-sensing receptor, proton-coupled amino acid transporter 2, hydroxycarboxylic acid receptor 3, sodium- and chloride-dependent neutral and basic amino acid transporter B(0+), receptor-interacting serine/threonine-protein kinase 1, and indoleamine 2,3-dioxygenase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn ii | New Drug Application | 2022-05-04 |
| aminosyn-pf | New Drug Application | 2022-07-21 |
| clinimix | New Drug Application | 2021-04-13 |
| clinimix e | New Drug Application | 2021-04-13 |
| clinisol | ANDA | 2018-06-01 |
| kabiven | New Drug Application | 2025-09-11 |
| optimax anticavity fluoride cotton candy | C200263 | 2025-05-12 |
| optimax anticavity fluoride watermelon | C200263 | 2025-05-12 |
| optimax purple anticavity fluoride | C200263 | 2025-09-02 |
| perikabiven | New Drug Application | 2025-09-15 |
Show 5 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
170 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | 1 | — | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 1 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 1 | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 2 | 1 | — | — | — | 2 |
| Gliosarcoma | D018316 | — | — | 2 | 1 | — | — | — | 2 |
| Melanoma | D008545 | — | — | 2 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
| Medulloblastoma | D008527 | — | — | 1 | — | — | — | — | 1 |
| Ependymoma | D004806 | — | — | 1 | — | — | — | — | 1 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tryptophan |
| INN | tryptophan |
| Description | L-tryptophan is the L-enantiomer of tryptophan. It has a role as an antidepressant, a nutraceutical, a micronutrient, a plant metabolite, a human metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is an erythrose 4-phosphate/phosphoenolpyruvate family amino acid, a proteinogenic amino acid, a tryptophan and a L-alpha-amino acid. It is a conjugate base of a L-tryptophanium. It is a conjugate acid of a L-tryptophanate. It is an enantiomer of a D-tryptophan. It is a tautomer of a L-tryptophan zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 73-22-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL54976 |
| ChEBI ID | 16828 |
| PubChem CID | 6305 |
| DrugBank | DB00150 |
| UNII ID | 8DUH1N11BX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC36A1
SLC36A1
Organism
Homo sapiens
Gene name
SLC36A1
Gene synonyms
PAT1
NCBI Gene ID
Protein name
proton-coupled amino acid transporter 1
Protein synonyms
lysosomal amino acid transporter 1, proton/amino acid transporter 1, solute carrier family 36 (proton/amino acid symporter), member 1, Solute carrier family 36 member 1
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 125,865 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aminosyn ii
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
448 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use